Trials / Completed
CompletedNCT02398240
Brentuximab for Newly Diagnosed Hodgkin Disease
A Pilot Study of Risk Adapted Therapy Utilizing Upfront Brentuximab With Combination Chemotherapy in the Treatment of Children, Adolescents and Young Adults With Newly Diagnosed Hodgkin Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Mitchell Cairo · Academic / Other
- Sex
- All
- Age
- 1 Year – 29 Years
- Healthy volunteers
- Not accepted
Summary
The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brentuximab Vedotin | Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg) |
| DRUG | Doxorubicin | Days: 1 and 15 Dose: 25 mg/m2/dose. |
| DRUG | Vincristine | Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose). |
| DRUG | Rituximab | Days: 2 and 16 Dose: 375 mg/m2/dose. |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2022-06-01
- Completion
- 2022-12-01
- First posted
- 2015-03-25
- Last updated
- 2023-10-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02398240. Inclusion in this directory is not an endorsement.